Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Leht 1 alates 18 tulemused
Induction heating apparatus for use in causing necrosis of neoplasm
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The invention set forth in this specification pertains to a new and improved method and apparatus for causing necrosis of neoplasm by hyperthermia.
Aberrant cells within the body, such as are frequently referred to as neoplasm, are the subject of a great deal of concern
Induction heating method for use in causing necrosis of neoplasm
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS REFERENCE TO RELATED APPLICATIONS
This application contains subject matter set forth in the co-pending U.S.A. application by the inventor named herein, Dr. Robert Rand et al., Ser. No. 223,727 filed Jan. 9, 1981 entitled "Induction Heating Method For Use In Causing Necrosis of Neoplasm" now
Inductive heating process for use in causing necrosis of neoplasms at selective frequencies
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
This invention is directed to a process of necrosing neoplasms as a result of hyperthermia of the neoplasm induced by hysteresis heating at selected frequencies of particles associated with the neoplasm.
It is a recognized medical fact that certain surgical invasions of
Compounds as inhibitor of tumor necrosis factor alpha release
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Release of such cytokines as tumor necrosis factor a (TNF-.alpha.) and transforming growth factor .alpha. (TGF-.alpha.) can cause adverse reactions ranging from psoriasis to sepsis. Many of these reactions are related to inflammation or autoimmune conditions, such as
Specialized perfusion protocol for whole-body hyperthermia
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to a specialized method for whole-body hyperthermia, including extracorporeal blood heating and dialysis, as an antiviral protocol.
BACKGROUND OF THE INVENTION
Hyperthermia as a treatment of tumors has been carefully studied and applied since the
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamide heteroarly hydroxamic acids as matrix metalloproteinase and TACE inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metaloproteinase and tace inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Preparation and use of .beta.-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme)
Remotely RF powered conformable thermal applicators
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
Embodiments of the present invention are generally related to apparatus and methodology of thermal applicators in cancer therapy. In particular, the present embodiments are directed to a technique called "nanoparticle ferromagnetic resonance heating," where ferromagnetic
Hydrazine derivatives
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Release of such cytokines as tumor necrosis factor .alpha.(TNF-.alpha.) and transforming growth factor .alpha.(TGF-.alpha.) can cause adverse reactions ranging from fever to sepsis. Many of these reactions are related to inflammation or autoinmuune conditions, such as
Methods of using IL-1 antagonists to treat autoinflammatory disease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
1. Field of the Invention
The invention relates to methods of using interleukin-1 (IL-1) antagonists to treat autoinflammatory diseases, such as, for example, including familial mediterranean fever (FMF), NOMID/CINCA, Muckle-Wells Syndrome, FCAS, and tumour necrosis factor
Methods of using IL-1 antagonists to treat autoinflammatory disease
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND
1. Field of the Invention
The invention relates to methods of using interleukin-1 (IL-1) antagonists to treat autoinflammatory diseases, such as, for example, including familial mediterranean fever (FMF), NOMID/CINCA, Muckle-Wells Syndrome, FCAS, and tumor necrosis factor
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
